In a controversial move, Merck is rolling back its commitment to provide a life-saving rotavirus vaccine to parts of West Africa at the same time the drug maker is ramping up supplies to China, where the product would reportedly be sold for a much higher price.

The company supplies its RotaTeq vaccine through an arrangement with GAVI, the Vaccine Alliance, a public-private partnership that helps provide medicines and vaccines to low-income countries. However, Merck is reducing shipments by one-third this year and next, according to GAVI. After that, supplies are not expected. About 4.7 million doses will be delivered this year and 4 million next year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy